To further explore the potential value of the NF-κB pathway in the clinical treatment of patients with KIRC, we plotted box plots based on drug susceptibility predictions in the GDSC database to determine the effect of the NF-κB pathway on IC50 of 12 commonly renal carcinoma targeted drugs. Here, NFKB1 is linked to renal carcinoma.